In a report released today, Charles Zhu from LifeSci Capital maintained a Hold rating on Repare Therapeutics (RPTX – Research Report). The ...

Investment analysts at Lifesci Capital issued their Q1 2025 earnings per share (EPS) estimates for shares of Perspective ...

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) saw unusually-high trading volume on Monday after HC ...

Discover Celcuity's Q4 2024 insights: gedatolisib's promising trials for breast cancer, $2B market potential, and key 2025 milestones.

Q4 2024 Earnings Call Transcript March 28, 2025 Humacyte, Inc. beats earnings expectations. Reported EPS is $-0.16, ...

LifeSci Capital is acting as the lead manager for the proposed offering. In another sign that the biotech IPO market is picking up, cell therapy specialist Kyverna has filed to raise roughly $211 ...

Good afternoon, ladies and gentlemen, and welcome to the Celcuity fourth quarter and full year 2024 financial results webcast conference call. (Operator Instructions) I would now like to turn the ...

Appointment of seven recognized experts is validating for Ventyx’s NLRP3 Program--AD/PD™ 2025 provides helpful insights on potential next steps ...

Chaim Lebovits; President, Chief Executive Officer; Brainstorm Cell Therapeutics Inc. Alla Patlis; Interim Chief ...